| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 4/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 2/6 |
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥1.55 |
| 52 Week High | CN¥2.92 |
| 52 Week Low | CN¥1.52 |
| Beta | 0.67 |
| 1 Month Change | 2.31% |
| 3 Month Change | -10.28% |
| 1 Year Change | -45.66% |
| 3 Year Change | -76.34% |
| 5 Year Change | -50.95% |
| Change since IPO | -54.28% |
Recent News & Updates
Recent updates
Shareholder Returns
| SFOS.F | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 1.2% | 1.1% | 0.7% |
| 1Y | -45.7% | 9.5% | 23.9% |
Return vs Industry: SFOS.F underperformed the US Pharmaceuticals industry which returned 9.5% over the past year.
Return vs Market: SFOS.F underperformed the US Market which returned 23.9% over the past year.
Price Volatility
| SFOS.F volatility | |
|---|---|
| SFOS.F Average Weekly Movement | 8.0% |
| Pharmaceuticals Industry Average Movement | 10.0% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: SFOS.F has not had significant price volatility in the past 3 months.
Volatility Over Time: SFOS.F's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1994 | 40,370 | Deyong Wen | www.fosunpharma.com |
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. develops, manufactures, and sells pharmaceutical products in Mainland China and internationally. It operates in five segments: Pharmaceutical Manufacturing, Medical Devices and Medical Diagnosis, Healthcare Service, Pharmaceutical Distribution and Retail, Other Business segments.
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Fundamentals Summary
| SFOS.F fundamental statistics | |
|---|---|
| Market cap | US$7.82b |
| Earnings (TTM) | US$277.60m |
| Revenue (TTM) | US$5.62b |
31.5x
P/E Ratio1.6x
P/S RatioIs SFOS.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SFOS.F income statement (TTM) | |
|---|---|
| Revenue | CN¥40.69b |
| Cost of Revenue | CN¥21.50b |
| Gross Profit | CN¥19.19b |
| Other Expenses | CN¥17.18b |
| Earnings | CN¥2.01b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.75 |
| Gross Margin | 47.16% |
| Net Profit Margin | 4.94% |
| Debt/Equity Ratio | 57.2% |
How did SFOS.F perform over the long term?
See historical performance and comparison